Loading stock data…
$16.03+0.55 (+3.55%)
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States.
Greenwich LifeSciences, Inc. in the Healthcare sector is trading at $16.03 with a market capitalization of $223M. Wall Street consensus targets $57.00 (2 analysts), implying a +255.6% move over the next 12 months. The stock is currently 53% below its 52-week high of $34.10, remaining 26.3% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$4.02M↑ | -$5.73M↑ | -$7.94M↓ | -$4.17M↓ | -$3.77M |
| Net Income | -$3.95M↑ | -$5.66M↑ | -$7.92M↓ | -$4.15M↓ | -$3.75M |
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane ...